Repare Therapeutics News

Express News | Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123

BenzingaApr 30 07:11 ET

Express News | Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition

ReutersApr 30 07:05 ET

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 32% Plummet

Unfortunately for some shareholders, the Repare Therapeutics Inc. (NASDAQ:RPTX) share price has dived 32% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twe

Simply Wall StApr 28 09:43 ET

Repare Therapeutics Announces Board Changes and FD Disclosure

TipRanksApr 26 16:36 ET

Express News | Repare Therapeutics Appoints Steven H. Stein, M.d. to Its Board of Directors

ReutersApr 26 16:05 ET

Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation

TipRanksApr 21 09:35 ET

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Market Cap Dropped US$21m Last Week; Private Equity Firms Bore the Brunt

Yahoo FinanceApr 20 09:43 ET

Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients

Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination with gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan (rituxi

BenzingaApr 15 08:56 ET

Form 144 | Repare Therapeutics(RPTX.US) Officer Proposes to Sell 481.42K in Common Stocks

SEC FILLINGS DISCLOSED/ Mar 26, $Repare Therapeutics(RPTX.US)$ Officer Segal Lloyd Mitchell intends to sell 99,466 shares of its common stock on Mar 26, with a total market value of approximately $481

moomoo NewsMar 26 14:55 ET

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...

Stockhouse Mar 17 11:00 ET

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK--(BUSINESS WIRE)--$RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. ("Repare"

BusinesswireMar 15 14:35 ET

Little Excitement Around Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues As Shares Take 30% Pounding

Repare Therapeutics Inc. (NASDAQ:RPTX) shares have had a horrible month, losing 30% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year for shareho

Simply Wall StMar 12 06:13 ET

Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead

TipRanksMar 8 06:35 ET

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming

BusinesswireFeb 29 07:05 ET

Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)

TipRanksFeb 28 14:50 ET

Repare Therapeutics Reports Promising 2023 Progress

TipRanksFeb 28 11:37 ET

Recap: Repare Therapeutics Q4 Earnings

Repare Therapeutics (NASDAQ:RPTX) reported its Q4 earnings results on Wednesday, February 28, 2024 at 07:05 AM.Here's what investors need to know about the announcement.EarningsRepare Therapeutics mis

BenzingaFeb 28 09:40 ET

Repare Therapeutics GAAP EPS of -$0.67 Misses by $0.34, Revenue of $13.05M Misses by $5.88M

Seeking AlphaFeb 28 07:50 ET

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023

Yahoo FinanceFeb 28 07:36 ET

Repare Therapeutics: Runway to Fund Operations Into Mid-2026 >RPTX

Repare Therapeutics: Runway to Fund Operations Into Mid-2026 >RPTX

Dow JonesFeb 28 07:07 ET